About the Company
Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CHMA News
Chiasma Plunges After FDA Rejects Application For Growth Disorder Drug
Shares of Chiasma are plunging this morning after the company said the FDA rejected the company's application for approval of a proposed treatment of adult patients with a growth disorder.
Todd Foley's Net Worth
Inc., Zalicus Inc., CHIASMA, INC, and Pacira Pharmaceuticals, Inc.. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news ...
Welcome to Inc.'s Directory of B2B Excellence
They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.
Acromegaly Treatment Market Booming with 7.7% CAGR | Market.us
According to a recent report by Market.us, the Global Acromegaly Treatment Market size is expected to be worth around USD 3.4 Billion by 2033 from USD 1.6 Billion in 2023, growing at a CAGR of 7.7% ...
Peptide–drug Conjugates (PDCs) Market Current Scenario with Future Trends Analysis to 2031
InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on “Global Peptide–drug Conjugates (PDCs) Market(By Product ( Lutetium Lu 177 dotatate, Melflufen, ANG1005, BT1718, ...
Admission to Trading on AIM
Amryt Pharma plc: IPO completed in 2016, acquired distressed and/or undervalued assets (Birken AG, Aegerion Pharmaceuticals Inc and Chiasma Inc), completed a trade sale in 2023 for US$1.48 billion.
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Snap Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
‘Food, Inc. 2’ Review: A Second Course
Share full article “Food, Inc. 2,” directed by Robert Kenner and Melissa Robledo, begins by describing how the last few years have shown the risks of letting a handful of mega-suppliers ...
Apple Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Nike Inc. Cl B
Under Armour Inc. Cl C-1.23% $2.88B Under Armour Inc. Cl A-1.34% $2.88B ...
Citigroup Inc. (C)
API attacks affected nearly one-quarter of organiza (Bloomberg) -- Edward Ruff has departed Citigroup Inc. after the firm put the senior dealmaker on leave while it was investigating his treatment ...
Loading the latest forecasts...